Cerebral Palsy Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Cerebral Palsy Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The cerebral palsy treatment market is expected to register a significant CAGR of 4.4% during the study period, 2022-2027.

In recent times, countries have faced a huge threat of COVID-19. As per the World Health Organization (WHO), coronavirus disease is an infectious disease, and most people infected with the COVID-19 virus will experience mild to moderate respiratory illness. COVID-19 has a considerable effect on all major organ systems. As per the study "Why Individuals With Cerebral Palsy Are At Higher Risk For Respiratory Complications From COVID-19" published in November 2020 stated that respiratory dysfunction is one of the leading causes of morbidity and mortality in individuals with cerebral palsy (CP). Individuals with pre-existing respiratory disorders are at greater risk for respiratory complications if they contract COVID-19, thereby increasing the risk of morbidity associated with cerebral palsy. Due to the COVID-19-led lockdown, there were supply chain disruptions in accessing the treatment for cerebral palsy. The emergence of telemedicine has helped in improving accessibility, significantly impacting the market. According to the study "Accelerating Telemedicine for Cerebral Palsy During the COVID-19 Pandemic and Beyond," published in June 2020, a multidisciplinary therapeutic presence is more accessible with telemedicine, bringing together various specialties and approaches to the child's natural environment. Telemedicine is expected to go beyond the COVID-19 era and will dominate during the study period, impacting the market growth.

The factors propelling the studied market growth are the growing burden of cerebral palsy, rise in investments, technological advancements, government initiatives, and other key strategies adopted by the key market players. According to the article published by Congress.gov in March 2022, cerebral palsy is the most common motor disability in children, affecting more than 1,000,000 Americans, 1 in 345 children, and over 17,000,000 people worldwide.

The growing research and development activities in the studied market are driving the market growth. For instance, as per clinicaltrials.gov, in January 2022, Neurocrine Biosciences initiated phase 3, a randomized, double-blind, placebo-controlled study to evaluate the efficacy of valbenazine versus placebo in participants aged 6 to 70 years for the treatment of dyskinesia due to cerebral palsy (DCP). The study is expected to be completed by August 2024. Positive responses from such studies evaluating the efficacies of existing treatments for cerebral epilepsy will increase its adoption, thus boosting the studied market during the study period.

Moreover, rising strategic initiatives such as mergers and partnerships by key market players will expand the offerings in the market, which will boost the studied market. For instance, in April 2022, the Japanese subsidiary of Control Bionics signed an exclusive distribution agreement with Double Research and Development Co., Ltd. To start full-scale operations to better solve the communication challenges of people with severe disabilities in Japan through technology. Control Bionics has been working with users living with severe disabilities, including cerebral palsy (CP) and others.

Rising investments in the market will propel technological innovation and expand the geographical presence, which will drive the market. For instance, in April 2022, Jupiter Lifeline Hospitals is planning to set up a state-of-the-art neuro-rehabilitation center in the United Kingdom with an investment of around 50 million pounds. The proposed rehabilitation center in the country is expected to have a 100-bed inpatient capacity, which will benefit patients with stroke, traumatic brain injury, cerebral palsy, spinal cord injury, Parkinson's disease, progressive and non-progressive neurological disorders, and sports injuries.

Therefore, owing to the aforementioned factors, the studied market is expected to grow significantly during the study period. However, the side effects of drugs associated with cerebral palsy are expected to hinder the market growth during the study period.

Key Market TrendsSpastic Cerebral Palsy Segment is Expected to Account for the Large Market Share Over the Forecast Period

Spastic cerebral palsy is a developmental disorder caused by damage to the brain before birth, during delivery, or within the first few years of life. This condition prevents the normal development of the motor function. Spastic cerebral palsy causes increased muscle tone, stiff muscles, and difficulty walking. Treatments for spastic cerebral palsy include physical therapy, medications, and surgery. The different types of spastic cerebral palsy are spastic diplegia, spastic Hemiplegia, and spastic Quadriplegia.

Factors such as high incidences of spastic cerebral palsy, rising research and development activities, and increasing investments are expected to significantly boost the studied market growth.

According to a March 2022 update of the article “Spastic Cerebral Palsy” published by CerebralPalsyGuidance.com, spastic cerebral palsy is the most common form of cerebral palsy, accounting for 70% to 80% of all people diagnosed. Therefore, due to the high burden of the diseases, there is an increasing demand for its therapeutics, thus boosting the investments and research activities in the segment, thus, contributing to the significant growth of the market.

The growing research activities in the segment will fuel the market. For instance, as per Clinicaltrials.gov, a study was initiated in November 2021 by Supernus Pharmaceuticals Inc. It is a phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial which is used to access the efficacy and safety of MYOBLOC for the treatment of upper limb spasticity in adults followed by an open-label extension safety trial. Positive results from such studies will increase its adoption, thus driving the market.

Moreover, the study “The safety and efficacy of umbilical cord blood mononuclear cells in individuals with spastic cerebral palsy: a randomized double-blind sham-controlled clinical trial” published in March 2022, demonstrated that intrathecal injection of umbilical cord blood mononuclear cell (UCB-MNC) was safe and effective in children with cerebral palsy.

Thus, due to the above-mentioned factors, the studied segment is expected to contribute to the significant growth of the market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The primary driving factors for the growth of the North American cerebral palsy market are the rising burden of cerebral palsy, growing research and development activities, increasing investments, supporting government initiatives, and key initiatives taken by the key market players.

The United States within North America is expected to hold a significant share of the studied market during the study period. For instance, According to the article published by Congress.gov in March 2022, in the United States, more than 10,000 babies are diagnosed with cerebral palsy each year. The high prevalence of cerebral palsy in the country is increasing the demand for its therapeutics. Therefore pharmaceutical companies are investing heavily in the therapeutic area, which will significantly drive the market.

Rising investments in the studied market will bring innovation in the studied market, thereby boosting the accessibility of therapeutics for cerebral palsy, fueling the market. For instance, in March 2022, Adam Boehler, in partnership with Martin Ventures, invested in StationMD, a healthcare company that uses telemedicine to deliver medical care to people with intellectual and developmental disabilities (I/DD). That includes individuals with autism spectrum disorder, Down syndrome, and cerebral palsy. This will increase the accessibility of treatments to people with cerebral palsy, thereby driving the market.

Additionally, in January 2022, Governor of New York Kathy Hochul invested in Cerebral Palsy Associations of New York State. This proposal includes USD 2 billion in workforce funding and USD 500 million in cost of living to support a sustainable care infrastructure and therefore focus on addressing the current workforce crisis.

Moreover, strategic initiatives adopted by key market players creating awareness for cerebral palsy are expected to drive market growth. For instance, in February 2022, Edward R. Matthews, CEO of ADAPT Community Network, and Armando A. Contreras, President, and CEO of United Cerebral Palsy, launched Start Here, a new digital platform that will provide caregivers with a trusted source for guidance on everything from the basics of cerebral palsy and other intellectual and developmental disabilities, as well as managed care advice about how to be an effective advocate for their child. This will create awareness for therapeutics for cerebral palsy, thus increasing its demand, which will lead to lucrative growth of the market.

Therefore, due to the above-mentioned factors, the studied market is expected to lead to lucrative growth of the market in North America.

Competitive Landscape

The studied market is fragmented and moderately competitive. The strategies such as mergers and acquisitions and partnerships adopted by key market players to expand their geographical reach and product offerings will drive the market growth. The key players in the market are AbbVie Inc., Ipsen Biopharmaceuticals Inc., Merz GmbH & Co. KGaA, Teva Pharmaceutical Industries Ltd, Supernus Pharmaceuticals Inc., and others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.